4SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
Planegg-Martinsried, Germany, 15 September 2023 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that renowned dermato-oncology key opinion leader and study investigator, Professor Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will give an oral presentation on the findings from its RESMAIN study investigating the efficacy of resminostat as a maintenance treatment for cutaneous T-cell lymphoma, at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting at the Leiden University Medical Center, the Netherlands, September 21-23.
